Alteogen Inc. (KOSDAQ: 196170), a South Korea-based biotechnology company, has announced an exclusive licensing agreement with Japan-headquartered Daiichi Sankyo (TYO: 4568). This strategic partnership grants Daiichi Sankyo worldwide rights to utilize Alteogen’s ALT-B4, a novel hyaluronidase based on Hybrozyme Technology, in the development and commercialization of a subcutaneous version of Enhertu (fam-trastuzumab deruxtecan-nxki), a HER2-directed antibody drug conjugate (ADC) co-developed and commercialized by AstraZeneca.
Financial Terms and Collaboration Details
Under the terms of the agreement, Daiichi Sankyo will make an undisclosed upfront payment to Alteogen and is committed to paying milestone payments upon the achievement of specified development, regulatory, and sales milestones. Additionally, Alteogen will receive tiered royalties from Daiichi Sankyo. Alteogen will be responsible for the clinical and commercial supply of ALT-B4 to Daiichi Sankyo, ensuring a smooth progression of the subcutaneous Enhertu project.
Significance of the Agreement
This agreement not only strengthens Daiichi Sankyo’s position in the global oncology market but also highlights Alteogen’s Hybrozyme Technology as a key enabler in the development of more patient-friendly drug delivery systems. The subcutaneous version of Enhertu has the potential to improve treatment accessibility and convenience for patients with HER2-positive cancers, further expanding the reach and impact of this innovative therapy.-Fineline Info & Tech
Leave a Reply